351 related articles for article (PubMed ID: 8236759)
1. An overview of current programs on drug development and regulation for small ruminants--pharmaceutical industry perspective.
Terry M
Vet Hum Toxicol; 1993; 35 Suppl 2():12-3. PubMed ID: 8236759
[No Abstract] [Full Text] [Related]
2. Extra-label drug use--pharmaceutical industry view.
Welser JR
J Am Vet Med Assoc; 1993 May; 202(10):1635-42;discussion 1654-8. PubMed ID: 8514571
[No Abstract] [Full Text] [Related]
3. Current FDA policy on use of human-labeled drugs in animals.
Teske RH
J Am Vet Med Assoc; 1993 May; 202(10):1632-3;discussion 1634. PubMed ID: 8514570
[No Abstract] [Full Text] [Related]
4. Implications for the FDA/Center for Veterinary Medicine (CVM).
Geyer RE
J Am Vet Med Assoc; 1993 May; 202(10):1718-23. PubMed ID: 8514592
[No Abstract] [Full Text] [Related]
5. Scientific basis for nonapproved use of drugs in veterinary practice.
Brumbaugh GW
J Am Vet Med Assoc; 1993 May; 202(10):1693-6;discussion 1713-7. PubMed ID: 8514586
[No Abstract] [Full Text] [Related]
6. Drug development for small ruminants: reflections on current status.
Anderson NV
Vet Hum Toxicol; 1993; 35 Suppl 2():4-5. PubMed ID: 8236766
[No Abstract] [Full Text] [Related]
7. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues.
Thomas JW
J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021
[No Abstract] [Full Text] [Related]
8. Impact of the Animal Drug Availability Act on veterinary practitioners and the animal health industry.
Troutman LM; Vaughn SD; Schmerfeld G; Beaulieu AJ
J Am Vet Med Assoc; 1997 Jun; 210(11):1597-600. PubMed ID: 9170084
[No Abstract] [Full Text] [Related]
9. Professional drug labeling.
Terry M
J Am Vet Med Assoc; 1993 May; 202(10):1711-2;discussion 1713-7. PubMed ID: 8514591
[No Abstract] [Full Text] [Related]
10. FDA responsibilities in regulation of drugs for use in animals: congressional perspective.
Zeller M
J Am Vet Med Assoc; 1993 May; 202(10):1609-12; discussion 1613-7. PubMed ID: 8514566
[No Abstract] [Full Text] [Related]
11. Professional responsibilities.
Jenkins WL
J Am Vet Med Assoc; 1993 May; 202(10):1742-3. PubMed ID: 8514601
[No Abstract] [Full Text] [Related]
12. FDA's regulation of prescription drug labeling: a role for implied preemption.
Kendrick LC
Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
[No Abstract] [Full Text] [Related]
13. AVMA legislation: partial solution to drug availability problem.
Gloyd JS
J Am Vet Med Assoc; 1993 Apr; 202(7):1055-6. PubMed ID: 8473213
[No Abstract] [Full Text] [Related]
14. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
15. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
Dorfman HL; Quinn VM; Brophy EA
Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
[No Abstract] [Full Text] [Related]
16. Extra-label rules: the final outcome.
Curry-Galvin E
J Am Vet Med Assoc; 1997 Jan; 210(1):10-2. PubMed ID: 8977639
[No Abstract] [Full Text] [Related]
17. Development of orphan products.
FDA Drug Bull; 1983 Apr; 13(1):2-4. PubMed ID: 6852406
[No Abstract] [Full Text] [Related]
18. The contribution of clinical pharmacology to new drug approvals.
Brown SA
J Am Vet Med Assoc; 1993 May; 202(10):1700-2;discussion 1713-7. PubMed ID: 8514588
[No Abstract] [Full Text] [Related]
19. Compounding forum: FDA-CVM hears veterinarians' views.
J Am Vet Med Assoc; 1993 Nov; 203(10):1367-72. PubMed ID: 8276690
[No Abstract] [Full Text] [Related]
20. The case for preemption of prescription drug failure-to-warn claims.
Kim CH
Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
[No Abstract] [Full Text] [Related]
[Next] [New Search]
